Dr. Christophe MassardChair of Drug Development Department (DITEP),
Gustave Roussy, Villejuif, France
Christophe is a medical oncologist with an MD and PhD. He is Chair of the Drug Development Department (DITEP), Gustave Roussy, Villejuif, France and also a Consultant Medical Oncologist, and cancer specialist at Gustave Roussy and the Drug Development Department (DDD). He is primarily involved in translational cancer research and the designing and running of early-phase biomarker-driven clinical trials, with a special interest in genitourinary cancer and the central nervous system.
He received his medical degree from PARIS XI University, and later obtained an MSc and PhD also from PARIS XI University. He completed his residency training in Paris Hospital, followed by a fellowship in medical oncology at Gustave Roussy. He is board certified in Medical Oncology and did a post-doctoral fellowship in Prof DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London). Christophe is a member of ESMO, ASCO, and AACR.
Over the last 5 years, he has been one of the principal investigators of 15 phase I trials, 1 phase II trial (prostate cancer), and sub investigator of more than 80 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to precision medicine (MOSCATO, MATCH R and PETRUS program).
Christophe has contributed to more than 180 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology. He is also a member of the editorial boards of Bulletin du Cancer, Investigational New Drugs, and European Journal of Cancer. Research axes: early clinical trials, precision medicine, GU cancers (prostate cancer, bladder cancer and testis), glioma, and circulating biomarkers.